• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Section 32 Raises $740 Million Venture Fund

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    $RLAY
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $COIN alert in real time by email

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare.

    "I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

    The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (NASDAQ:COIN), Crowdstrike (NASDAQ:CRWD), Relay Therapeutics (NASDAQ:RLAY), Thrive Earlier Detection (NASDAQ:EXAS), and Vir Biotechnology (NASDAQ:VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

    Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

    With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

    "I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

    Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

    About Section 32

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html

    SOURCE Section 32

    Get the next $COIN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COIN
    $CRWD
    $EXAS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    CrowdStrike Holdings Inc.
    $CRWD
    3/11/2026$490.00Sell → Buy
    DZ Bank
    CrowdStrike Holdings Inc.
    $CRWD
    3/10/2026$510.00Equal-Weight → Overweight
    Morgan Stanley
    CrowdStrike Holdings Inc.
    $CRWD
    3/4/2026$555.00 → $500.00Outperform
    BMO Capital Markets
    CrowdStrike Holdings Inc.
    $CRWD
    3/3/2026$450.00Overweight
    Wells Fargo
    CrowdStrike Holdings Inc.
    $CRWD
    3/2/2026$520.00Neutral → Overweight
    Piper Sandler
    Vir Biotechnology Inc.
    $VIR
    2/24/2026$19.00Outperform → Strong Buy
    Raymond James
    CrowdStrike Holdings Inc.
    $CRWD
    2/13/2026$446.00Hold → Buy
    HSBC Securities
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    More analyst ratings

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CrowdStrike upgraded by DZ Bank with a new price target

    DZ Bank upgraded CrowdStrike from Sell to Buy and set a new price target of $490.00

    3/11/26 8:28:44 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    CrowdStrike upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded CrowdStrike from Equal-Weight to Overweight and set a new price target of $510.00

    3/10/26 8:36:54 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    BMO Capital Markets reiterated coverage on CrowdStrike with a new price target

    BMO Capital Markets reiterated coverage of CrowdStrike with a rating of Outperform and set a new price target of $500.00 from $555.00 previously

    3/4/26 8:21:27 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Better and Coinbase Launch the First Token-Backed, Conforming Mortgage

    By integrating home finance with digital assets, millions of Americans can now achieve their homeownership goals by pledging BTC or USDC without needing to liquidate their holdings or potentially triggering a taxable event1. Better Home & Finance Holding Company (NASDAQ:BETR), and Coinbase (NASDAQ:COIN), today announced a milestone partnership to bring token-backed mortgages to millions of Americans. Token-backed mortgages are originated and serviced by Better, the leading AI-native mortgage originator, and benefit from the same backing of Fannie Mae as other conforming mortgages. Bitcoin (BTC) and USDC pledges are powered by Coinbase, the largest and most trusted cryptocurrency exchange

    3/26/26 8:30:00 AM ET
    $BETR
    $COIN
    Finance: Consumer Services
    Finance

    CrowdStrike and IBM Expand Strategic Collaboration to Accelerate Agentic SOC Transformation

    Expanded strategic collaboration brings together Charlotte AI with IBM ATOM for coordinated, machine-speed response and integrates the Falcon platform with IBM Consulting's managed security services and X-Force Cyber Range RSA 2026--CrowdStrike (NASDAQ:CRWD) and IBM today announced an expansion of their strategic collaboration to advance agentic SOC transformation. The expanded collaboration integrates CrowdStrike® Charlotte AI™ with IBM's Autonomous Threat Operations Machine (ATOM), IBM's autonomous SOC orchestration engine, for coordinated, machine-speed investigation and containment. It also extends the CrowdStrike Falcon® platform into IBM Consulting's managed Threat Detection and R

    3/25/26 5:15:00 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    CrowdStrike and AWS Announce Jazz as the Winner of the 2026 Cybersecurity Startup Accelerator, Supported by NVIDIA Inception

    RSA 2026 – CrowdStrike (NASDAQ:CRWD) today announced Jazz as the winner of the third annual Cybersecurity Startup Accelerator with Amazon Web Services (AWS) and NVIDIA through the NVIDIA Inception program. Jazz was recognized for its innovation in AI-driven data loss prevention (DLP) and its potential to address critical security challenges facing modern enterprises in the AI era. The 2026 accelerator attracted nearly 1,000 startups from around the world, reflecting a new generation of founders building AI-driven cloud security innovation. Thirty-five startups were selected for the eight-week, equity-free program, working closely with experts from CrowdStrike, AWS, NVIDIA, and the broader

    3/25/26 2:41:00 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Podbere Burt W.

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    3/27/26 8:00:07 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Oleary Denis

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    3/27/26 8:00:06 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Saha Anurag

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    3/24/26 8:00:10 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vir Biotechnology Inc.

    SCHEDULE 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    3/27/26 1:55:01 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

    SCHEDULE 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    3/27/26 11:34:53 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

    SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    3/26/26 6:24:16 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    CrowdStrike Appoints Andy Nowinski as Vice President of Investor Relations and Strategic Finance

    CrowdStrike (NASDAQ:CRWD) today announced Andy Nowinski as Vice President of Investor Relations and Strategic Finance. Andy now leads the company's investor relations strategy, strengthening engagement with the global investment community and driving strategic financial initiatives that support the company's long-term growth as CrowdStrike advances its position as the industry's first hyperscaler of security. "Andy's blend of investment acumen, technical depth, and sector expertise makes him uniquely qualified for this role," said Burt Podbere, CFO of CrowdStrike. "His disciplined understanding of market structure, operating performance, and the long-term drivers of cybersecurity will ensu

    12/2/25 8:05:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Financials

    Live finance-specific insights

    View All

    CrowdStrike Reports Fourth Quarter and Fiscal Year 2026 Financial Results

    Surpasses $5 billion ending ARR milestone, accelerates to 24% year-over-year growth to reach $5.25 billion Net new ARR grows 47% year-over-year and reaches a record $331 million in Q4 Achieves positive GAAP net income and record non-GAAP net income in the quarter Delivers record operating and free cash flow for both the quarter and year Reaches $1.69 billion in ending ARR from Falcon Flex accounts, up over 120% year-over-year CrowdStrike Holdings, Inc. (NASDAQ:CRWD), today announced financial results for the fourth quarter and fiscal year 2026, ended January 31, 2026. "FY26 will go down in our history books as CrowdStrike's best year yet," said George Kurtz, CrowdStrike's

    3/3/26 4:05:00 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer – Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety profile and promising anti-tumor activity – Strong financial position with $781.6 million in cash and investments as of December 31, 2025 – Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. "This is a seminal moment for Vir Biotechnology

    2/23/26 5:14:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

    – Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date – Dose-dependent anti-tumor activity was observed, with 82% PSA50 and 53% PSA90 declines and RECIST-evaluable objective responses (45% ORR in 5/11 patients) in ≥3,000 µg/kg Q3W dosing cohorts – Vir Biotechnology to host conference call today at 5:30 p.m. ET / 2:30 p.m. PT – Data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium on February 26 (Oral Abstract #17) Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new data from the ongoing Phase 1 clinical tri

    2/23/26 5:02:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:44:24 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:40:50 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by CrowdStrike Holdings Inc.

    SC 13G/A - CrowdStrike Holdings, Inc. (0001535527) (Subject)

    11/14/24 1:22:38 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology